Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. www.nature.com › articles › s44161/024/00504-1A renaissance of cerebral cavernous malformation proteins in ......

    Hace 4 días · Cerebral cavernous malformations (CCMs) are rare cerebrovascular anomalies characterized by abnormal capillary-venous growth, recurrent lesions and even stroke-like symptoms.

  2. Imágenes

    • Cranial nerves within the cavernous sinus | AMI 2018 Meeting | Cranial ...
    • Cranial nerves within the cavernous sinus | AMI 2018 Meeting | Cranial ...
    • The cerebral veins drain the brain parenchyma and are located in the ...
    • Normal Anatomy of the cerebral venous system | Anatomy, Brain anatomy ...
    • Cranial Nerve Anatomy - YouTube

    Ver todo

  3. stockhouse.com › news › press-releases2024-07-01 | Ovid Therapeutics and Graviton Bioscience ... -...

    Hace 23 horas · Ovid is developing: OV888/GV101 capsule, a potent and highly selective ROCK2 inhibitor capsule, for the potential treatment of cerebral cavernous malformations and other rare CNS diseases; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other ...

  4. www.jornada.com.mx › estudio-revela-crecimiento-constante-del-cerebro-humano-997Estudio revela crecimiento constante del cerebro humano

    Hace 23 horas · 01 de julio de 2024 10:49. Washington. Un nuevo estudio de la Universidad de California Davis Health reveló que el cerebro humano es cada vez más grande, lo que podría conducir a un aumento de la reserva cerebral. Según el estudio, publicado en la revista Jama Neurology, ese incremento puede genera también la reducción potencial del ...

  5. www.tmcnet.com › usubmit › 2024/07/01Ovid Therapeutics and Graviton Bioscience Announce Topline Data...

    Hace 23 horas · Ovid is developing: OV888/GV101 capsule, a potent and highly selective ROCK2 inhibitor capsule, for the potential treatment of cerebral cavernous malformations and other rare CNS diseases; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other ...

  6. markets.businessinsider.com › news › stocksOvid Therapeutics and Graviton Bioscience Announce ... - Markets...

    Hace 23 horas · About Cerebral Cavernous Malformations CCMs are one of the most common vascular malformations in the central nervous system (CNS), with a prevalence of approximately 400,000 symptomatic ...

  7. csimarket.com › news › ovid-therapeutics-and-graviton-bioscience-reveal-promising#Ovid Therapeutics and Graviton Bioscience Reveal Promising...

    Hace 23 horas · Conclusion The favorable Phase 1 clinical trial results for OV888/GV101 capsule signify a noteworthy milestone in the quest to find effective treatments for cerebral cavernous malformations. As Ovid Therapeutics Inc. and Graviton Bioscience Corporation prepare for the subsequent Phase 2 clinical study, there is renewed hope for advancements in therapy for patients affected by this complex ...

  8. newsnetwork.mayoclinic.org › es › 2024/06/26Investigadores identifican cambios vasculares en el cerebro ...

    Hace 5 días · Los investigadores planean seguir estudiando la molécula SMAD3 y sus consecuencias vasculares y neurodegenerativas en la enfermedad de Alzheimer y también planean investigar otras moléculas con una posible participación en el mantenimiento de la barrera hematoencefálica.